Symbols / BJDX Stock $1.90 -3.11% Bluejay Diagnostics, Inc.
BJDX (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force. The company also develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. In addition, it develops additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure, as well as other tests using the Symphony platform. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Ratings
Current target
$1.90
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2023-08-03 | down | Dawson James | Buy → Neutral | — |
- Bluejay nears finish line in sepsis test study with 624 patients - Stock Titan ue, 07 Apr 2026 07
- BJDX Ownership | BLUEJAY DIAGNOSTICS INC (NASDAQ:BJDX) - ChartMill Mon, 20 Apr 2026 07
- Bluejay Diagnostics Stock Plummets 37% With 11-Day Losing Streak - Trefis ue, 23 Dec 2025 08
- Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split - Yahoo Finance ue, 27 Jan 2026 08
- Is Bluejay Diag (BJDX) stock risky (Slight Dip) 2026-04-20 - Social Flow Trades - Cổng thông tin điện tử Tỉnh Sơn La Mon, 20 Apr 2026 07
- Bluejay Diagnostics (BJDX) Stock Rockets on Expanded Partnership: A Game-Changer for Sepsis Testing? - RagingBull hu, 09 Oct 2025 07
- Sepsis test maker builds supply for 10M rapid kits as key trial advances - Stock Titan ue, 17 Feb 2026 08
- Bluejay Diagnostics stock soars after expanding manufacturing partnership - Investing.com hu, 09 Oct 2025 07
- Is Bluejay Diag (BJDX) stock risky (Slight Dip) 2026-04-20 - Crowd Sentiment Stocks - Cổng thông tin điện tử tỉnh Lào Cai Mon, 20 Apr 2026 07
- Bluejay Diagnostics says all prefunded warrants exercised; ~972,000 shares outstanding, 1.5M cash-exercise warrants - TradingView Fri, 20 Feb 2026 08
- Board seeks flexible reverse split, plan increase at Bluejay Diagnostics (NASDAQ: BJDX) - Stock Titan Mon, 20 Apr 2026 20
- Are insiders buying or selling Bluejay Diag (BJDX) Stock | Price at $1.95, Up 3.17% - Pro Trader Recommendations - Cổng thông tin điện tử tỉnh Lào Cai hu, 02 Apr 2026 07
- Bluejay Diagnostics announces 1-for-4 reverse stock split - Investing.com ue, 27 Jan 2026 08
- Bluejay Diagnostics Announces $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules - Yahoo Finance hu, 09 Oct 2025 07
- Medical diagnostics firm ends prefunded warrants, flags 13G share confusion - Stock Titan Fri, 20 Feb 2026 08
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.25
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.25
|
| Cost Of Revenue |
|
—
|
—
|
0.00
-100.00%
|
0.20
|
| Reconciled Cost Of Revenue |
|
—
|
—
|
0.00
-100.00%
|
0.20
|
| Gross Profit |
|
—
|
—
|
0.00
-100.00%
|
0.05
|
| Operating Expense |
|
6.95
-3.02%
|
7.17
-30.47%
|
10.31
+10.08%
|
9.37
|
| Research And Development |
|
3.05
-12.25%
|
3.47
-39.25%
|
5.71
+37.63%
|
4.15
|
| Selling General And Administration |
|
3.91
+5.64%
|
3.70
-19.55%
|
4.60
-11.85%
|
5.21
|
| Selling And Marketing Expense |
|
0.00
-100.00%
|
0.01
-97.07%
|
0.28
-37.21%
|
0.45
|
| General And Administrative Expense |
|
3.91
+5.88%
|
3.69
-14.46%
|
4.31
-9.45%
|
4.76
|
| Other Gand A |
|
3.91
+5.88%
|
3.69
-14.46%
|
4.31
-9.45%
|
4.76
|
| Other Operating Expenses |
|
—
|
—
|
—
|
—
|
| Total Expenses |
|
6.95
-3.02%
|
7.17
-30.47%
|
10.31
+7.78%
|
9.57
|
| Operating Income |
|
-6.95
+3.02%
|
-7.17
+30.47%
|
-10.31
-10.66%
|
-9.32
|
| Total Operating Income As Reported |
|
-6.95
+3.02%
|
-7.17
+30.47%
|
-10.31
-10.66%
|
-9.32
|
| EBITDA |
|
-6.68
+0.28%
|
-6.70
+27.01%
|
-9.17
-1.79%
|
-9.01
|
| Normalized EBITDA |
|
-6.68
+0.28%
|
-6.70
+27.01%
|
-9.17
-4.55%
|
-8.77
|
| Reconciled Depreciation |
|
0.17
-14.27%
|
0.20
-74.51%
|
0.78
+154.91%
|
0.31
|
| EBIT |
|
-6.85
+0.68%
|
-6.89
+30.73%
|
-9.95
-6.83%
|
-9.32
|
| Total Unusual Items |
|
—
|
—
|
0.00
+100.00%
|
-0.24
|
| Total Unusual Items Excluding Goodwill |
|
—
|
—
|
0.00
+100.00%
|
-0.24
|
| Special Income Charges |
|
—
|
—
|
0.00
+100.00%
|
-0.24
|
| Other Special Charges |
|
—
|
—
|
—
|
—
|
| Impairment Of Capital Assets |
|
—
|
—
|
0.00
-100.00%
|
0.24
|
| Net Income |
|
-6.85
+11.26%
|
-7.72
+22.46%
|
-9.95
-7.07%
|
-9.30
|
| Pretax Income |
|
-6.85
+11.26%
|
-7.72
+22.46%
|
-9.95
-7.07%
|
-9.30
|
| Net Non Operating Interest Income Expense |
|
0.10
+114.28%
|
-0.68
-510.68%
|
0.16
+83.89%
|
0.09
|
| Interest Expense Non Operating |
|
0.00
-99.90%
|
0.82
|
0.00
|
0.00
|
| Net Interest Income |
|
0.10
+114.28%
|
-0.68
-510.68%
|
0.16
+83.89%
|
0.09
|
| Interest Expense |
|
0.00
-99.90%
|
0.82
|
0.00
|
0.00
|
| Interest Income Non Operating |
|
0.10
-33.10%
|
0.15
-11.57%
|
0.16
+83.89%
|
0.09
|
| Interest Income |
|
0.10
-33.10%
|
0.15
-11.57%
|
0.16
+83.89%
|
0.09
|
| Other Income Expense |
|
0.01
-93.98%
|
0.13
-32.95%
|
0.19
+379.51%
|
-0.07
|
| Other Non Operating Income Expenses |
|
0.01
-93.98%
|
0.13
-32.95%
|
0.19
+14.23%
|
0.17
|
| Gain On Sale Of Security |
|
—
|
—
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-6.85
+11.26%
|
-7.72
+22.46%
|
-9.95
-7.07%
|
-9.30
|
| Net Income From Continuing Operation Net Minority Interest |
|
-6.85
+11.26%
|
-7.72
+22.46%
|
-9.95
-7.07%
|
-9.30
|
| Net Income From Continuing And Discontinued Operation |
|
-6.85
+11.26%
|
-7.72
+22.46%
|
-9.95
-7.07%
|
-9.30
|
| Net Income Continuous Operations |
|
-6.85
+11.26%
|
-7.72
+22.46%
|
-9.95
-7.07%
|
-9.30
|
| Normalized Income |
|
-6.85
+11.26%
|
-7.72
+22.46%
|
-9.95
-9.87%
|
-9.06
|
| Net Income Common Stockholders |
|
-6.85
+67.30%
|
-20.94
-110.38%
|
-9.95
-7.07%
|
-9.30
|
| Otherunder Preferred Stock Dividend |
|
0.00
-100.00%
|
13.22
|
0.00
|
—
|
| Diluted EPS |
|
—
|
-456.75
+96.45%
|
-12,860.32
+12.71%
|
-14,733.67
|
| Basic EPS |
|
—
|
-456.75
+96.45%
|
-12,860.32
+12.71%
|
-14,733.67
|
| Basic Average Shares |
|
—
|
0.05
+5823.51%
|
0.00
+22.66%
|
0.00
|
| Diluted Average Shares |
|
—
|
0.05
+5823.51%
|
0.00
+22.66%
|
0.00
|
| Diluted NI Availto Com Stockholders |
|
-6.85
+67.30%
|
-20.94
-110.38%
|
-9.95
-7.07%
|
-9.30
|
| Line Item | Trend | 2022-12-31 |
|---|---|---|
| Total Assets |
|
13.52
|
| Current Assets |
|
11.79
|
| Cash Cash Equivalents And Short Term Investments |
|
10.11
|
| Cash And Cash Equivalents |
|
10.11
|
| Inventory |
|
—
|
| Prepaid Assets |
|
1.43
|
| Current Deferred Assets |
|
0.00
|
| Assets Held For Sale Current |
|
—
|
| Other Current Assets |
|
0.24
|
| Total Non Current Assets |
|
1.73
|
| Net PPE |
|
1.70
|
| Gross PPE |
|
2.29
|
| Accumulated Depreciation |
|
-0.60
|
| Properties |
|
0.00
|
| Buildings And Improvements |
|
0.47
|
| Machinery Furniture Equipment |
|
0.14
|
| Construction In Progress |
|
0.38
|
| Other Properties |
|
1.73
|
| Leases |
|
0.04
|
| Goodwill And Other Intangible Assets |
|
0.00
|
| Other Intangible Assets |
|
0.00
|
| Other Non Current Assets |
|
0.04
|
| Total Liabilities Net Minority Interest |
|
1.98
|
| Current Liabilities |
|
1.64
|
| Payables And Accrued Expenses |
|
1.47
|
| Payables |
|
0.64
|
| Accounts Payable |
|
0.64
|
| Current Accrued Expenses |
|
0.84
|
| Current Debt And Capital Lease Obligation |
|
0.17
|
| Current Capital Lease Obligation |
|
0.17
|
| Total Non Current Liabilities Net Minority Interest |
|
0.34
|
| Long Term Debt And Capital Lease Obligation |
|
0.32
|
| Long Term Capital Lease Obligation |
|
0.32
|
| Other Non Current Liabilities |
|
0.02
|
| Preferred Securities Outside Stock Equity |
|
—
|
| Stockholders Equity |
|
11.54
|
| Common Stock Equity |
|
11.54
|
| Capital Stock |
|
0.00
|
| Common Stock |
|
0.00
|
| Share Issued |
|
0.00
|
| Ordinary Shares Number |
|
0.00
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
28.54
|
| Retained Earnings |
|
-17.00
|
| Total Equity Gross Minority Interest |
|
11.54
|
| Total Capitalization |
|
11.54
|
| Working Capital |
|
10.15
|
| Invested Capital |
|
11.54
|
| Total Debt |
|
0.49
|
| Capital Lease Obligations |
|
0.49
|
| Net Tangible Assets |
|
11.54
|
| Tangible Book Value |
|
11.54
|
| Current Notes Payable |
|
—
|
| Dueto Related Parties Current |
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-6.05
+22.60%
|
-7.82
+5.93%
|
-8.31
-7.39%
|
-7.74
|
| Cash Flow From Continuing Operating Activities |
|
-6.05
+22.60%
|
-7.82
+5.93%
|
-8.31
-7.39%
|
-7.74
|
| Net Income From Continuing Operations |
|
-6.85
+11.26%
|
-7.72
+22.46%
|
-9.95
-7.07%
|
-9.30
|
| Depreciation Amortization Depletion |
|
0.17
-14.27%
|
0.20
-74.51%
|
0.78
+154.91%
|
0.31
|
| Depreciation |
|
0.17
-14.27%
|
0.20
-74.51%
|
0.78
+154.91%
|
0.31
|
| Depreciation And Amortization |
|
0.17
-14.27%
|
0.20
-74.51%
|
0.78
+154.91%
|
0.31
|
| Other Non Cash Items |
|
—
|
0.31
+23468.05%
|
0.00
|
—
|
| Stock Based Compensation |
|
0.00
-99.97%
|
0.02
-89.38%
|
0.19
-56.29%
|
0.43
|
| Asset Impairment Charge |
|
—
|
—
|
0.00
-99.25%
|
0.24
|
| Operating Gains Losses |
|
0.04
+1158.78%
|
0.00
+90.88%
|
0.00
+1204.38%
|
0.00
|
| Gain Loss On Investment Securities |
|
—
|
—
|
—
|
—
|
| Gain Loss On Sale Of PPE |
|
0.04
+1158.78%
|
0.00
+90.88%
|
0.00
+1204.38%
|
0.00
|
| Change In Working Capital |
|
0.58
+191.80%
|
-0.63
-194.97%
|
0.67
+15.24%
|
0.58
|
| Change In Receivables |
|
—
|
—
|
—
|
—
|
| Changes In Account Receivables |
|
—
|
—
|
—
|
—
|
| Change In Inventory |
|
—
|
—
|
—
|
0.00
|
| Change In Prepaid Assets |
|
0.33
+122.11%
|
0.15
-83.77%
|
0.93
+2371.70%
|
-0.04
|
| Change In Payables And Accrued Expense |
|
0.22
+121.12%
|
-1.04
-291.67%
|
-0.27
-142.00%
|
0.63
|
| Change In Accrued Expense |
|
0.15
+121.69%
|
-0.70
-2197.48%
|
-0.03
-109.00%
|
0.34
|
| Change In Payable |
|
0.07
+119.96%
|
-0.35
-46.91%
|
-0.24
-179.41%
|
0.30
|
| Change In Account Payable |
|
0.07
+119.96%
|
-0.35
-46.91%
|
-0.24
-178.88%
|
0.30
|
| Change In Other Working Capital |
|
—
|
0.27
|
—
|
—
|
| Change In Other Current Assets |
|
0.03
+514.80%
|
-0.01
-200.70%
|
0.01
+146.14%
|
-0.01
|
| Investing Cash Flow |
|
-0.17
+43.37%
|
-0.31
+56.43%
|
-0.70
+41.28%
|
-1.20
|
| Cash Flow From Continuing Investing Activities |
|
-0.17
+43.37%
|
-0.31
+56.43%
|
-0.70
+41.28%
|
-1.20
|
| Net PPE Purchase And Sale |
|
-0.17
+43.37%
|
-0.31
+56.43%
|
-0.70
+41.28%
|
-1.20
|
| Purchase Of PPE |
|
-0.17
+43.37%
|
-0.31
+56.43%
|
-0.70
+41.28%
|
-1.20
|
| Capital Expenditure |
|
-0.17
+43.37%
|
-0.31
+56.43%
|
-0.70
+41.28%
|
-1.20
|
| Financing Cash Flow |
|
7.09
-30.63%
|
10.22
+819.52%
|
1.11
+13665.47%
|
0.01
|
| Cash Flow From Continuing Financing Activities |
|
7.09
-30.63%
|
10.22
+819.52%
|
1.11
+13665.47%
|
0.01
|
| Net Issuance Payments Of Debt |
|
-0.00
-7.27%
|
-0.00
+21.91%
|
-0.00
-500.12%
|
-0.00
|
| Issuance Of Debt |
|
0.00
-100.00%
|
2.00
|
0.00
|
0.00
|
| Repayment Of Debt |
|
-0.00
+99.80%
|
-2.00
-41584.09%
|
-0.00
-500.12%
|
-0.00
|
| Long Term Debt Issuance |
|
0.00
-100.00%
|
2.00
|
0.00
|
0.00
|
| Long Term Debt Payments |
|
-0.00
+99.80%
|
-2.00
-41584.09%
|
-0.00
-500.12%
|
-0.00
|
| Net Long Term Debt Issuance |
|
-0.00
-7.27%
|
-0.00
+21.91%
|
-0.00
-500.12%
|
-0.00
|
| Net Common Stock Issuance |
|
8.35
-30.84%
|
12.07
+658.66%
|
1.59
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.00
-100.00%
|
0.00
|
0.00
-100.00%
|
0.03
|
| Net Other Financing Charges |
|
-1.25
+32.11%
|
-1.84
-288.82%
|
-0.47
-2272.36%
|
-0.02
|
| Changes In Cash |
|
0.86
-58.78%
|
2.09
+126.48%
|
-7.91
+11.49%
|
-8.93
|
| Beginning Cash Position |
|
4.30
+94.79%
|
2.21
-78.17%
|
10.11
-46.90%
|
19.05
|
| End Cash Position |
|
5.16
+20.06%
|
4.30
+94.79%
|
2.21
-78.17%
|
10.11
|
| Free Cash Flow |
|
-6.23
+23.38%
|
-8.13
+9.87%
|
-9.02
-0.86%
|
-8.94
|
| Interest Paid Supplemental Data |
|
—
|
—
|
0.00
+258.52%
|
0.00
|
| Common Stock Issuance |
|
8.35
-30.84%
|
12.07
+658.66%
|
1.59
|
0.00
|
| Issuance Of Capital Stock |
|
8.35
-30.84%
|
12.07
+658.66%
|
1.59
|
0.00
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-07 View
- 8-K2026-03-17 View
- 8-K2026-03-16 View
- 8-K2026-03-12 View
- 10-K2026-03-06 View
- 8-K2026-03-06 View
- 8-K2026-02-20 View
- 8-K2026-02-18 View
- 8-K2026-01-30 View
- 8-K2025-12-30 View
- 8-K2025-11-10 View
- 10-Q2025-11-07 View
- 8-K2025-10-14 View
- 8-K2025-10-09 View
- 8-K2025-08-15 View
- 8-K2025-08-11 View
- 10-Q2025-08-07 View
- 8-K2025-07-28 View
- 8-K2025-06-20 View
- 8-K2025-06-04 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|